Hepatotoxicity has become noted in clients receiving cabotegravir or rilpivirine. Monitoring of liver chemistries is usually recommended. Discontinue CABENUVA if hepatotoxicity is suspected.). The examine satisfied all its Major and important secondary endpoints, demonstrating that therapy with fruquintinib resulted in statistically substantial and